Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 86Neoplasms 3Osteoporosis 2Neoplasm Metastasis 2Lower Urinary Tract Symptoms 2Hirsutism 2Bulbo-Spinal Atrophy, X-Linked 2Breast Neoplasms 2Stage I Prostate Adenocarcinoma AJCC v7 1Sexual Dysfunction, Physiological 1Salivary Gland Neoplasms 1Primary Dysautonomias 1Ovarian Neoplasms 1Kidney Diseases 1Hypertension 1Gynecomastia 1Fallopian Tube Neoplasms 1Erectile Dysfunction 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms, Male 1Adenocarcinoma 1

Interventions

bicalutamide 2Mifepristone 2Corlux 2Waist-Hip Ratio 1Waist Circumference 1Time 1Metformin 1Insulin 1Folic Acid 1Flutamide 1Ethinyl Estradiol 1Cyproterone Acetate 1Cardiovascular Physiological Phenomena 1Body Mass Index 1Body Composition 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Hirsutism × bicalutamide × Clear all
NCT00959335 2017-03-28

Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fasting Conditions

Sandoz

Phase 1 Completed
36 enrolled
Genitourinary

Hirsutism, Prostatic Neoplasms

NCT00960310 2017-03-28

Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fed Conditions

Sandoz

Phase 1 Completed
36 enrolled
Genitourinary

Hirsutism, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡